Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
In recent years, whole-cell-based screens for novel small molecule inhibitors active against Mycobacterium tuberculosis in culture followed by the whole-genome sequencing of spontaneous resistant mutants have identified multiple chemical scaffolds thought to kill the bacterium through the inactivation of the mycolic acid transporter, MmpL3. Consistent with the fact that MmpL3 is required for the formation of the mycobacterial outer membrane, we have conclusively shown in this study, using conditionally regulated knockdown mutants, that mmpL3 is required for the replication and viability of M. tuberculosis , both under standard laboratory growth conditions and during the acute and chronic phases of infection in mice. Speaking for the vulnerability of this target, silencing mmpL3 had a rapid bactericidal effect on actively replicating cells in vitro and reduced by 3 to 5 logs in less than 4 weeks the bacterial loads of acutely and chronically infected mouse lungs, respectively. Depletion of MmpL3 further rendered M. tuberculosis hypersusceptible to MmpL3 inhibitors. The exquisite vulnerability of MmpL3 at all stages of the infection establishes this transporter as an attractive new target with the potential to improve and shorten current drug-susceptible and drug-resistant tuberculosis chemotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141 · cited 3×
“against nonreplicating hypoxic or nutrient-starved bacilli (17, 23),”
BackgroundMethodHoffmann, C., Leis, A., Niederweis, M., Plitzko, J. M., & Engelhardt, H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709530105 · Cited by 596
Direct Visualization of the Outer Membrane of Mycobacteria and Corynebacteria in Their Native State
Zuber, B., Chami, M., Houssin, C., Dubochet, J., Griffiths, G., & Daffé, M. (2008) · Journal of Bacteriology · doi:10.1128/jb.01919-07 · Cited by 458
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442 · cited 2×
“tuberculosis is consistent with our previous demonstration that this transporter is required for the growth of Mycobacterium smegmatis (5) and the report of an unsuccessful attempt to disrupt mmpL3 in M.”
MethodResultSelf-citationMartin, A., Camacho, M., Portaels, F., & Palomino, J. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3616-3619.2003 · Cited by 306
Li, W., Upadhyay, A., Fontes, F. L., North, E. J., Wang, Y., Crans, D. C., Grzegorzewicz, A. E., Jones, V., Franzblau, S. G., Lee, R. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03229-14 · Cited by 202 · cited 3×
“tuberculosis H37Rv mc(2)6206, grown in the presence of different concentrations of ATc, to various control drugs (isoniazid, rifampin, and ciprofloxacin) and MmpL3 inhibitors (adamantyl urea compound number 36 and indolcarboxamide IC2418) (17, 35) were determined using two types of assays: the resazurin blue test in 9…”
BackgroundMethodSelf-citationDiscovery and characterization of a unique mycobacterial heme acquisition system
Tullius, M. V., Harmston, C. A., Owens, C. P., Chim, N., Morse, R. P., McMath, L. M., Iniguez, A., Kimmey, J. M., Sawaya, M. R., Whitelegge, J. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009516108 · Cited by 199 · cited 1×
“to the proposed role of MmpL3 in heme iron import (40, 41) is”
BackgroundPuckett, S., Trujillo, C., Eoh, H., Marrero, J., Spencer, J., Jackson, M., Schnappinger, D., Rhee, K., & Ehrt, S. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004144 · Cited by 72 · cited 3×
“, the fructose-1,6-bisphosphate aldolase Fba (27), the biotin biosynthetic enzyme BioA (37), the decaprenyl-phosphoribose 2= epimerase DprE1 (38), the phosFIG 6 Effect of depleting MmpL3 on the susceptibility of M.”
BackgroundSelf-citation
Cited by
The mycobacterial cell envelope — a moving target
Dulberger, C. L., Rubin, E. J., & Boutte, C. C. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0273-7 · Cited by 365
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
NTM drug discovery: status, gaps and the way forward
Wu, M.-L., Aziz, D. B., Dartois, V., & Dick, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.04.001 · Cited by 276
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target
Zhang, B., Li, J., Yang, X., Wu, L., Zhang, J., Yang, Y., Zhao, Y., Zhang, L., Yang, X., Yang, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.003 · Cited by 263
MmpL3 is the flippase for mycolic acids in mycobacteria
Xu, Z., Meshcheryakov, V. A., Poce, G., & Chng, S.-S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700062114 · Cited by 201
“In this regard, drugs inhibiting MmpL3, which has been shown to be an ideal target (33), would be especially important.”
BackgroundDirect Inhibition of MmpL3 by Novel Antitubercular Compounds
Li, W., Stevens, C. M., Pandya, A. N., Darzynkiewicz, Z., Bhattarai, P., Tong, W., Gonzalez-Juarrero, M., North, E. J., Zgurskaya, H. I., & Jackson, M. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00048 · Cited by 97
Self-citationHeme and hemoglobin utilization by Mycobacterium tuberculosis
Mitra, A., Ko, Y.-H., Cingolani, G., & Niederweis, M. (2019) · Nature Communications · doi:10.1038/s41467-019-12109-5 · Cited by 81
Cell Walls and Membranes of Actinobacteria
Rahlwes, K. C., Sparks, I. L., & Morita, Y. S. (2019) · Subcellular Biochemistry · doi:10.1007/978-3-030-18768-2_13 · Cited by 65
Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic target
Adams, O., Deme, J. C., Parker, J. L., Fowler, P. W., Lea, S. M., & Newstead, S. (2021) · Structure · doi:10.1016/j.str.2021.06.013 · Cited by 63
Metadata
- Authors
- Li, W., Obregón-Henao, A., Wallach, J. B., North, E. J., Lee, R. E., Gonzalez-Juarrero, M., Schnappinger, D., & Jackson, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-09
- Volume
- 60
- Issue
- 9
- Pages
- 5198-5207
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2420893966
- Cited by
- 117
- References
- 9
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.